NASDAQ:SNGX

Soligenix (SNGX) Stock Forecast, Price & News

$0.72

+0.02 (+2.18%)

(As of 05/26/2023 08:47 PM ET)

Compare

Today's Range: $0.68
▼
$0.74
50-Day Range: $0.71
▼
$2.29
52-Week Range: $0.65
▼
$15.00

Volume: 212,200 shs
Average Volume: 555,702 shs
Market Capitalization: $2.16 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Soligenix MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
4.37% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.43
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($5.55) to ($3.06) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.03 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Soligenix.

3.0

Short Interest

Percentage of Shares Shorted
4.37% of the float of Soligenix has been sold short.
Short Interest Ratio / Days to Cover
Soligenix has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Soligenix has recently increased by 62.99%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Soligenix does not currently pay a dividend.
Dividend Growth
Soligenix does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SNGX.

1.9

News and Social Media Coverage

News Sentiment
Soligenix has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Soligenix this week, compared to 2 articles on an average week.
Search Interest
32 people have searched for SNGX on MarketBeat in the last 30 days. This is an increase of 967% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Soligenix to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Soligenix insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.99% of the stock of Soligenix is held by insiders.
Percentage Held by Institutions
Only 7.17% of the stock of Soligenix is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Soligenix are expected to grow in the coming year, from ($5.55) to ($3.06) per share.

See Top Rated MarketRank™ Stocks Here

About Soligenix (NASDAQ:SNGX) Stock

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Receive SNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter.

SNGX Stock News Headlines

May 16, 2023 | finanznachrichten.de

Soligenix, Inc.: Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results

May 16, 2023 | finance.yahoo.com

Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis

May 29, 2023 | Stocks To Trade (Ad)

3 Free Stock Picks per Day

Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.

May 15, 2023 | finance.yahoo.com

Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results

May 11, 2023 | finance.yahoo.com

Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma

May 9, 2023 | finance.yahoo.com

Soligenix Announces Closing of $8.5 Million Public Offering

May 5, 2023 | finance.yahoo.com

Soligenix Announces Pricing of $8.5 Million Public Offering

May 4, 2023 | finance.yahoo.com

Why Are Soligenix Shares Trading Higher Today

May 29, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

May 3, 2023 | finance.yahoo.com

Soligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of Directors

May 1, 2023 | finance.yahoo.com

Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease

April 24, 2023 | finance.yahoo.com

SNGX: Planning for Second Phase 3 Study for HyBryte™ in CTCL…

April 24, 2023 | finance.yahoo.com

Soligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma

April 14, 2023 | msn.com

Soligenix Shares Tumble as FDA Demands More Data

April 14, 2023 | msn.com

Soligenix stock sinks as FDA seeks additional positive results for cancer drug

April 14, 2023 | finance.yahoo.com

Soligenix Provides Regulatory Update on HyBryte™

April 5, 2023 | finance.yahoo.com

Soligenix Receives USAN Approval for "Hypericin Sodium" as Nonproprietary Name for Novel Active Ingredient in HyBryte™ and SGX302

April 5, 2023 | americanbankingnews.com

Soligenix, Inc. Expected to Earn Q1 2023 Earnings of ($1.25) Per Share (NASDAQ:SNGX)

April 3, 2023 | finance.yahoo.com

SNGX: Meeting with FDA to Discuss Refusal to File Letter…

April 3, 2023 | finance.yahoo.com

Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

March 31, 2023 | finance.yahoo.com

Soligenix Announces Recent Accomplishments And Year-End 2022 Financial Results

February 16, 2023 | finance.yahoo.com

Soligenix, Inc: Vital Vaccine Development Program has Potential to Address Future Marburg Virus Outbreaks

February 14, 2023 | investorplace.com

Why Is Soligenix (SNGX) Stock Down 27% Today?

February 14, 2023 | investorplace.com

Why Is Soligenix (SNGX) Stock Down 35% Today?

February 14, 2023 | prnewswire.com

Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

February 9, 2023 | finance.yahoo.com

Soligenix Announces Reverse Stock Split

January 19, 2023 | finance.yahoo.com

Soligenix Invited to Present at the Virtual Investor Summit Event

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive SNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter.

SNGX Company Calendar

Last Earnings: 11/12/2021
Today: 5/29/2023
Next Earnings (Estimated): 8/11/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SNGX
CUSIP: N/A
CIK: 812796
Web: www.soligenix.com
Phone: (609) 538-8200
Fax: 609-452-6467
Employees: 13
Year Founded: 1987

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-13,800,000.00
Net Margins: -996.96%
Pretax Margin: -1,218.01%
Return on Equity: -589.84%
Return on Assets: -64.89%

Debt

Debt-to-Equity Ratio: 6.67
Current Ratio: 0.94
Quick Ratio: 0.94

Sales & Book Value

Annual Sales: $950,000.00
Price / Sales: 2.27
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.14) per share
Price / Book: -0.64

Miscellaneous

Outstanding Shares: 2,980,000
Free Float: 2,857,000
Market Cap: $2.16 million
Optionable: Not Optionable
Beta: 1.74

Social Links

Key Executives

Christopher J. Schaber
Chairman, President & Chief Executive Officer

Jonathan L. Guarino
Chief Financial Officer, Secretary & Senior VP

Oreola Donini
Chief Scientific Officer & Senior Vice President

Richard C. Straube
Chief Medical Officer & Senior Vice President

Adam T. Rumage
VP-Regulatory Affairs & Project Management

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SNGX Stock - Frequently Asked Questions

How have SNGX shares performed in 2023?: Soligenix's stock was trading at $0.4520 on January 1st, 2023. Since then, SNGX shares have increased by 60.4% and is now trading at $0.7250.
View the best growth stocks for 2023 here.
Are investors shorting Soligenix?: Soligenix saw a increase in short interest in May. As of May 15th, there was short interest totaling 350,100 shares, an increase of 63.0% from the April 30th total of 214,800 shares. Based on an average daily trading volume, of 835,000 shares, the short-interest ratio is currently 0.4 days. Approximately 4.4% of the shares of the company are sold short.
View Soligenix's Short Interest.
When is Soligenix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our SNGX earnings forecast.
How were Soligenix's earnings last quarter?: Soligenix, Inc. (NASDAQ:SNGX) issued its earnings results on Friday, November, 12th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.03. The biopharmaceutical company earned $0.19 million during the quarter, compared to analyst estimates of $0.80 million. Soligenix had a negative trailing twelve-month return on equity of 589.84% and a negative net margin of 996.96%.
What other stocks do shareholders of Soligenix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV), T2 Biosystems (TTOO), Trevena (TRVN), Vaxart (VXRT), OPKO Health (OPK), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Actinium Pharmaceuticals (ATNM).

What is Soligenix's stock symbol?: Soligenix trades on the NASDAQ under the ticker symbol "SNGX."
Who are Soligenix's major shareholders?: Soligenix's stock is owned by many different institutional and retail investors. Top institutional investors include First Wilshire Securities Management Inc. (0.78%) and Geode Capital Management LLC (0.73%). Insiders that own company stock include Christopher J Schaber, Jerome B Zeldis, Jonathan L Guarino and Richard Straube.
View institutional ownership trends.
How do I buy shares of Soligenix?: Shares of SNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Soligenix's stock price today?: One share of SNGX stock can currently be purchased for approximately $0.73.
How much money does Soligenix make?: Soligenix (NASDAQ:SNGX) has a market capitalization of $2.16 million and generates $950,000.00 in revenue each year.
How can I contact Soligenix?: Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The official website for the company is www.soligenix.com. The biopharmaceutical company can be reached via phone at (609) 538-8200, via email at ir@soligenix.com, or via fax at 609-452-6467.

This page (NASDAQ:SNGX) was last updated on 5/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Soligenix (SNGX) Stock Forecast, Price & News

Soligenix MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows